trending Market Intelligence /marketintelligence/en/news-insights/trending/tbihgfsm08hmapujy444wa2 content esgSubNav
In This List

Antibe, Kwang Dong Pharmaceutical partner to develop anti-inflammatory drug

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Antibe, Kwang Dong Pharmaceutical partner to develop anti-inflammatory drug

Antibe Therapeutics Inc. and Kwang Dong Pharmaceutical Co. Ltd. signed a licensing deal to develop and commercialize anti-inflammatory drug ATB-346 in South Korea.

Under the agreement, Antibe will get C$13 million in development and commercial milestone payments, including C$1.3 million in up-front payment. The company will also receive a double-digit royalty on the South Korean net sales of the medicine, once commercialized.

ATB-346 is an anti-inflammatory drug being developed by Antibe to prevent ulcers and bleeding in the gastrointestinal tract due to non-steroidal anti-inflammatory drugs. The company has completed a phase 2b gastrointestinal safety study of the drug, in which ATB-346 was shown to be safer for the gastrointestinal tract than naproxen, a nonsteroidal anti-inflammatory drug that is widely used for treating pain but is associated with causing gastrointestinal ulceration and bleeding.

The Toronto-based company intends to begin a phase 2b dose-ranging efficacy study of the drug in September.

MedCI LLC acted as adviser on the transaction.